Keyword: Johnson & Johnson
J&J has escaped a $72 million verdict in its ongoing talcum powder saga, the first reversal of its numerous losses.
Under a growing biosim assault, Johnson & Johnson's big-selling immunology biologic Remicade held its ground again.
In the wake of Hurricane Maria, J&J says the company's Puerto Rico manufacturing plants "fared well," but "intermittent" shortages could follow.
J&J’s Stelara has plenty of new competition in the adult psoriasis market, so it’s gone where many of its rivals haven’t: the adolescent population.
Ebola vaccines from GlaxoSmithKline and Merck elicited antibody responses that lasted one year after vaccination, according to new research.
How many prescriptions does it take to find the right antidepressant? J&J's Healthy Minds video series tackles that question.
The verdicts in a string of pharma antitrust suits could transform how drugmakers strike contracts with payers, one analyst predicts.
BDO sifted through SEC filings to discover just what the top 100 life sciences companies are most worried about these days.
Johnson & Johnson will invest $350 million to expand a biologics plant in Ireland where it makes the APIs for a number of its top sellers.
Bayer stopped a trial of Xarelto in the secondary prevention of stroke and embolism, but it's not backing off ambitious sales projections for the drug.